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ABSTRACT 
Obesity is a complex disease caused by the interaction of a myriad of genetic, dietary, lifestyle, and environmental factors, which 
favors a chronic positive energy balance, and leads to increased body fat mass. The incidence of obesity is rising at an alarming rate 
and is becoming a major public health concern with incalculable social costs. Indeed, obesity facilitates the development of 
metabolic disorders such as diabetes, hypertension, and cardiovascular diseases in addition to chronic diseases such as stroke, 
osteoarthritis, sleep apnea, some cancers, and inflammation based pathologies. Standard reference Sibutramine produced a 
significant anti obesity activity in HFD induced obesity in rats. Alogliptin with medium and high doses exhibited a significant anti 
obesity activity by reducing the body weight, food intake, organ and fat pads weight and serum GLU, CHO, TRG, LDL and VLDL 
cholesterol levels with an increased HDL levels in HFD induced obesity models in rats. 
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INTRODUCTION 
In the present Evaluation, we have selected a Alogliptin 
(Anti diabetic drug) in which variety of pharmacological 
features are abundant. However to date anti-obesity 
activities of this Drug have not been reported. Its 
medicinal properties of dipeptidyl peptidase 4 inhibitors 
(DPP-4) reported by the researchers to opt for the 
assessment of anti-obesity activities in various 
experimental animal models. 
Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel oral 
antihyperglycemic agents for treating type 2 diabetes 
mellitus patients. Recent studies suggest that several 
DPP-4 inhibitors exert suppressing inflammatory 
reactions. However, whether or not DPP-4 inhibitors 
used as Anti-cancer drug. Alogliptin (2-({6-[(3R)-3-
aminopiperidinyl-1-yl]-3-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)yl} methyl)benzonitrile 
monobenzoate) (AGP) is a selective DPP-4 inhibitor 
that has  improves glycemic control. However, it 
remains unknown whether AGP has anti-cancer
1-7
. 
DPP4 was first discovered by Hopsu-Havu and Glenner 
in 1966. This protein is also called CD26 and is a 
ubiquitously expressed 110-kDa glycoprotein that be-
longs to the type 2 transmembrane protein family. As a 
member of the serine peptidase/prolyl oligopeptidase 
family, DPP4 is often sub classified based on its 
structure and function as follows: membrane-bound 
peptidase (fibroblast activation protein (FAP)/seprase), 
resident cytoplasmic enzyme (DPP8 and DPP9), and 
nonenzymatic member (DPP6 and DPP10). These 
proteins share a typical α/β-hydrolase fold. DPP4 
comprises four domains: a short cytoplasmic domain, a 
transmembrane domain, a flexible stalk segment, and 
the extracellular domain, which is further separated by a 
glycosylated region, the cysteine-rich region, and the 
catalytic region. DPP4 can cleave dozens of peptides, 
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including chemokines, neuropeptides, and regulatory 
peptides, containing a proline or alanine residue at 
position 2 of the amino-terminal region. Despite the 
preference for prolines at position 2, alternate residues at 
the penultimate position are also cleaved by DPP4, 
indicating a required stereochemistry for cleavage. This 
DPP4 cleavage at post-proline peptide bonds inactivates 
peptides and/ or generates new bioactive peptides, 
thereby regulating diverse biological processes
8-11
. 
Obesity is a chronic disease consisting of the increase in 
body fat stores. However, measuring body fat requires 
quite sophisticated methods that make population-based 
measure of body fat almost impossible to perform. 
Consequently, there are not precisely defined normal 
values of body fat. Thus, for practical reasons, obesity is 
measured by means of the Body Mass Index (BMI), a 
calculation taking into account theweight for a given 
height: BMI is given as a ratio of Weight (kg)/height 
(m)
2
 and highly correlates with total body fat and is very 
useful for epidemiological purposes. Based on the BMI 
and on its relationship with death from all causes, the 
WHO has established different cut-off points enabling 
the classification of obesity
12
. 
The psychogenic theory of obesity long held that obesity 
resulted from an emotional disorder in which food 
intake, relieved the anxiety and depression to which 
obese persons are usually susceptible. Stress associated 
with traumatic emotional events has been held 
responsible for certain cases of obesity and has been 
implicated in the pathogenesis of eating disorders such 
as night-eating syndrome and bulimia
13-17
. 
The exact etiology of obesity is unclear. The multiple 
causative factors like genetic, environmental, nutritional, 
physiological, psychological, social and cultural factors 
have been linked to its development and progression
18-
21
. 
Over the last few decades obesity research has been 
characterized by a dramatic change in the overall 
understanding about the adipose tissue and its role in 
pathophysiology. The secretory nature of adipocytes or 
fat cells which encompass 95 % of total body cells has 
shifted the concept of white adipose tissue (WAT) as a 
mere energy storing organ to that of an extremely active 
endocrine tissue. The large number of secreted proteins 
includes hormones, growth factors, enzymes, cytokines, 
complement factors, and matrix proteins, collectively 
termed as adipokines or adipocytokines. Since in obesity 
the adipose tissue is in a state of hypertrophy and the 
secretary activity of WAT is believed to be exaggerated 
and closely associated with obesity induced metabolic 
syndrome. Amid all these secreted products cytokines or 
better described as pro-inflammatory cytokines are 
thought to be fore-runners in obesity associated 
metabolic syndrome
22
. 
Sibutramine offers three types of benefit in weight 
management like enhancement of weight loss, 
improvement in weight maintenance and reduction in 
comorbidities. The mechanism of action of sibutramine 
involves two complimentary physiological effects, first 
it promotes and prolongs satiety after eating thereby 
reduces food intake, including snack consumption. 
Secondly it stimulates energy expenditure and limits the 
decline in metabolic rate that normally accompanies 
weight loss. Sibutramine has two fold pharmacological 
actions in that it is a monoamine reuptake inhibitor, and 
is particularly effective in blocking the reuptake of both 
Serotonin and Noradrenaline
23
. 
Obesity is caused by an imbalance between energy 
intake and consumption. It is frequently associated with 
dyslipidemia, cardiovascular risks, hypertension, and 
type-2 diabetes mellitus, and thus is recognized as one 
of the most serious public health problems. Numerous 
drugs targeted towards inhibition of amylase/α-
glucosidase/lipase, loss of appetite, and improving fatty 
acid metabolism, have been approved for the treatment 
of obesity; however, most of them have been withdrawn 
from the market because of their serious adverse effects. 
Therefore, many studies have been conducted to find 
and develop a new anti-obesity drug or a dietary 
supplement with lesser side effects
24-26
. 
MATERIALS AND METHODS 
Experimental animals: 
Albino rats (Wistar strain) of either sex weighing 
between 150-200 g and Albino mice 16-25 g were 
procured from National Centre for Laboratory Animal 
Sciences, C/0 Sri. Venkateswara Enterprises, Bangalore 
for experimental purpose. Then the animals were 
acclimatized for 7 days under standard husbandry 
condition.i.e
27
. 
Room temperature-           26 ± 2
0
C 
Relative humidity-             45 - 55% 
Light/dark cycle-               12 : 12h 
The animals were fed with a synthetic standard diet 
from Amrut Laboratories & Pranav Agro Industries Ltd. 
Sangli, Maharashtra. Water was allowed ad libitum 
under strict hygienic conditions. All animal studies were 
performed in accordance to Guidelines No. 425 of 
CPCSEA and Institutional Animal Ethical Committee 
(IAEC) of Innovative College of Pharmacy, Greater 
Noida, U.P. CPCSEA registration number was 
1346/PO/Re/S/10/CPCSEA and all the procedures were 
followed as per rules and regulations. 
Chemicals: 
All chemicals used were of analytical grade. 
Sibutramine (Symed Laboratories, Hyderabad,India) was 
used as Standard control. Test compound (Alogliptin) 
was provided by Taj Pharma, Mumbai, India. 
Grouping of animals: The animals are divided into 6 
groups of six rats in each group and the treatment given 
once. 
Method for collection of blood sample
28-31
 
On the 41st day the blood (up to2.5 ml) collected from 
retro-orbital puncture under the influence of light ether 
anesthesia into centrifuge tubes, which were centrifuged 
at 3000 rpm at room temperature. Anti-obesity activity 
of the drug was determined by measuring serum levels 
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of enzymes (GLU, CHO, TRG, HDL, VLDL, LDL) and 
Liver weight, Uterus Fat Pads, Mesentric Fat Pads). 
Statistical analysis: 
All results will be expressed as mean ± SEM from 6 
animals. Statistical difference in mean will be analyzed 
using one-way ANOVA (analysis of variance) followed 
by Post hoc test (Dunnett‘s‘t’ test). P< 0.05*, 0.01** and 
0.001
***
 will be considered as statistically significant
 
RESULTS 
Biochemical parameters 
In normal control animals glucose level is noted as 
103.35 mg/dL. A significant increase (P < 0.01) in 
serum glucose level is noted in HFD induced obese rats 
as 311.13mg/dL. Sibutramine (5 mg/kg) significantly (P 
< 0.01) reduced the glucose level in HFD induced obese 
rats i.e.; 110.7 mg/dL. Alogliptin also significantly (P < 
0.01) reduced the serum glucose level in a dose 
dependent manner i.e. 165.83, 111.12 and 104.75mg/dL 
respectively (Table 1 and Fig.1). 
In normal control animals serum cholesterol is noted as 
74.12 mg/dL. Asignificant increase (P < 0.01) in 
cholesterol level is noted in HFD induced obese rats as 
184.55 mg/dL. Sibutramine (5 mg/kg) significantly (P < 
0.01) reduced the serum cholesterol level in HFD 
induced obese rats i.e.; 102.29 mg/dL. Alogliptin 
significantly (P < 0.05) reduced the serum cholesterol 
with high doses only i.e. 120.44 mg/dL. But low and 
medium doses of the Alogliptin also reduced the serum 
cholesterol non significant extent i.e. 153.30 and 132.73 
mg/dL respectively (Table 1 and Fig.2). 
In normal control animals serum triglycerides level is 
noted as 94.25 mg/dL. A significant increase (P < 0.01) 
in serum triglycerides level is noted in HFD induced 
obese rats as 217.35 mg/dL. Sibutramine (5 mg/kg) 
significantly (P < 0.01) reduce the triglycerides level in 
HFD induced obese rats i.e.; 122.78 mg/dL. Alogliptin 
also significantly reduce the serum triglycerides level in 
dose dependent manner i.e. 159.33(P< 0.05), 156.02(P < 
0.05) and 155.88 mg/dL (P < 0.05) respectively (Table 1 
and Fig.3) 
In normal control animals serum HDL cholesterol level 
is noted as 20.19 mg/dL. A significant decrease (P < 
0.01) in HDL cholesterol level is noted in HFD induced 
obese rats as 14.0 mg/dL. Sibutramine (5 mg/kg) 
significantly (P < 0.01) increased theHDL cholesterol 
level in HFD induced obese rats i.e; 36.7 mg/dL. 
Alogliptinsignificantly (P < 0.01) increased the serum 
HDL cholesterol levels at medium and high doses i.e. 
16.1 and 21.94 mg/dL respectively. At low doses 
Alogliptinexhibited a non significant increase in serum 
HDL cholesterol levels i.e. 31.01mg/dL respectively 
(Table 1 and Fig.4) 
In normal control animals VLDL cholesterol level is 
noted as 18.85 mg/dL. A significant increase (P < 0.01) 
in serum VLDL cholesterol level is noted in HFD 
induced obese rats as 43.47 mg/dL. Sibutramine 
significantly (P < 0.01) reduced the serum VLDL 
cholesterol level in HFD induced obese rats i.e.; 24.55 
mg/dL. Alogliptin also significantly reduced the serum 
VLDL cholesterol level in dose a dependent manner 
i.e.31.86 (P < 0.05), 31.20 (P < 0.05) and 31.17 mg/dL 
(P < 0.05) respectively (Table 1 and Fig.5). 
In normal control animals LDL cholesterol level is 
noted as 38.57 mg/dL. A significant increase (P < 0.01) 
in serum LDL cholesterol level is noted in HFD induced 
obese rats as 207.27 mg/dL. Sibutramine (5 mg/kg) 
significantly (P < 0.01) reduced the serum LDL 
cholesterol level in HFD induced obese rats i.e.; 70.91 
mg/dL. Alogliptin also significantly (P < 0.05) reduced 
the serum LDL cholesterol level at high doses only 
noted as 90.73mg/dL, Low and medium doses of 
Alogliptin reduced serum LDL cholesterol level to non 
significant extent as 147.46and 104.87 mg/dL 
respectively (Table 2 and Fig.6). 
In normal control animals liver weight is noted as 3.39 
g. A significant increase (P< 0.01) in liver weight is 
noted in HFD induced obese rats as 4.75 g. Sibutramine 
(5mg/kg) significantly (P < 0.01) reduced the liver 
weight in HFD induced obese rats i.e.3.71 g. Alogliptin 
significantly (P < 0.01) reduced the liver weight 
withmedium and high doses recorded as 4.22, and 3.96 
g. Low doses of Alogliptin also reduced the liver weight 
to non significant extent noted as 4.55 g (P>0.05) 
respectively (Table 2 and Fig.7). 
In normal control animals uterus fat pads weight is 
noted as 3.34 g. A significant increase (P < 0.01) in 
uterus fat pads is noted in HFD induced obese rats as 
5.26 g. Sibutramine (5 mg/kg) significantly (P < 0.01) 
reduced the uterus fat pads in HFD induced obese rats 
i.e.; 3.97 g. Alogliptin also significantly (P < 0.01) 
reduced the uterus fat pads in dose a dependent manner 
i.e. 4.85, 4.60 and 4.24 g respectively (Table 2 and 
Fig.8). 
In normal control animals mesentric fat pads weight is 
noted as 1.71 g. A significant increase (P < 0.01) in 
mesentric fat pads weight is noted in HFD induced 
obese rats as 3.25 g. Sibutramine (5 mg/kg) significantly 
(P < 0.01) reduced the mesentric fat pads in HFD 
induced obese rats i.e; 2.09 g. Alogliptin also 
significantly (P <0.01) reduced the mesenteric fat pads 
weight in dose a dependent manner i.e. 2.96, 2.63 and 
2.34 g respectively (Table 2 and Fig.9). 
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Table 1: Effect of Alogliptin on serum biochemical parameters in HFD induced obesity in rats. 
Group Treatment GLU CHO TRG HDL VLDL 
I Normal Pellet diet 103.35± 4.4 74.12± 8.06 94.25± 6.9 20.19± 1.3 18.85± 1.3 
II HFD  311.13± 23.5 184.55± 20.28 217.35± 23.8 14.0± 0.5 43.47± 4.7 
III SBT  110.7± 4.7 102.29± 7.79 122.78±5.1 36.7± 3.4 24.55± 1.0 
IV Alogliptin 1mg/kg 165.83± 30.8 153.30± 14.63 159.33± 8.2 31.01± 1.4 31.86± 1.6 
V Alogliptin 2mg/kg 111.12± 4.8 132.73± 12.9 156.02± 10.08 21.94± 1.1 31.20± 2.0 
VI Alogliptin 3mg/kg 104.75± 4.4 120.44± 18.09 155.88± 11.8 16.1± 0.45 31.17± 2.3 
 
Table 2: Effect of Alogliptin on serum biochemical parameters in HFD induced obesity in rats. 
Group Treatment LDL Liver weight Uterus Fat Pads  Mesentric Fat Pads 
I Normal Pellet diet 38.57± 2.11 3.39± 0.09 3.34± 0.10 1.71± 0.03 
II HFD  207.27± 3.16 4.75± 0.05 5.26± 0.02 3.25± 06 
III SBT  70.91± 4.50 3.71± 0.06 3.97± 0.12 2.09± 0.08 
IV Alogliptin 1mg/kg 147.46± 3.64 4.55± 0.09 4.85± 0.05 2.96± 0.08 
V Alogliptin 2mg/kg 104.87± 4.66 4.22± 0.08 4.60± 0.03 2.63± 0.06 
VI Alogliptin 3mg/kg 90.73± 8.49 3.96± 0.17 4.24± 0.05 2.34± 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Effect of Alogliptin on serum glucose level (mg/dL) in High Fed Diet (HFD)   induced obesity in rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Effect of Alogliptin on serum cholesterol (mg/dL) in High Fed Diet (HFD) induced obesity in rats 
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Figure 3: Effect of Alogliptin on serum triglycerides (mg/dL)in High Fed Diet (HFD) induced obesity in rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Effect of Alogliptin on serum HDL cholesterol (mg/dL) in High Fed Diet (HFD) induced obesity in rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Effect of Alogliptin on serum VLDL cholesterol (mg/dL) in High Fed Diet (HFD) induced obesity in rats 
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Figure 6: Effect of Alogliptin on serum LDL cholesterol (mg/dL) in High Fed Diet (HFD) induced obesity in rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Effect of Alogliptin on liver weight (g/100g) in High Fed Diet (HFD) induced obesity in rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Effect of Alogliptin on uterus fat pads (g/100g) in High Fed Diet (HFD) induced obesity in rats 
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Figure 9: Effect of Alogliptin on mesentric fat pads (g/100g) in High Fed Diet (HFD) induced obesity in rats 
 
DISCUSSION 
In recent years there is a raise in development of anti 
obesity, anti cancer and anti inflammatory drugs as the 
incidence it is very high, multifactorial in nature with 
complexity and also lack of knowledge about the weight 
controlling system, even with cancer and inflammation 
strenuous research no effective medicament has come 
out as a one drug sofar. The main approach to control 
body weight rely on expenditure, thermogenesis, control 
of available substrate to cell and tissue through 
hormonal and other metabolic factors controlling the fate 
of available energy substrates, lethal obesity finally 
control of fat reserves through modification of 
eipogenesis and hipolysis in white adipose tissue.
13-21
  
Sibutramine is a serotonin–noradrenaline reuptake 
inhibitor (SNRI). A reuptake inhibitor inhibits the 
neuronal uptake of neurotransmitters and prolongs the 
duration of responses to both exogenous and neuronal 
release, in this case, of serotonin (5-HT) and 
noradrenaline (NA). Sibutramine has also been shown to 
block the reuptake of dopamine (DA) but at about a 
threefold lower potency when compared to 5-HT and 
NA. More recent studies suggest that sibutramine 
increases extracellular DA concentrations at similar 
levels to 5-HT in an animal model. 5-HT is recognized 
to have an influence on food intake and macronutrient 
selection. 
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The standard treatment of obesity is the use of High fed 
diets, often supplemented with exercise, food education 
and changes in eating habits. At present, the only option 
available to the severely obese is bariatric surgery, since 
relapses are extremely common with all treatments and 
in the morbidly obese most individual treatments do not 
achieve even a significant weight loss paralleled by 
improvement in the overall condition of the patient. In 
spite of its considerable danger and drawbacks, bariatric 
surgery is currently used as a last-resort therapy for life-
threatening obesity. 
High Fed Diet (HFD) is a widely used model of obesity. 
Presenting a varied and energy dense diet often leads to 
hyperphagia and weight gain. The ability of rats to select 
their own food items (and macronutrient content) 
introduces another source of variability between HFD. 
HFD contains with a variety of highly palatable, energy 
rich, high carbohydrate foods elicited significant 
increase in body weights and fat pad mass. HFD have 
been previously reported to increase energy intake and 
cause obesity in humans as well as animals.
 
It is well known that hyperlipidemia is the leading risk 
factor for atherosclerosis. Epidemiological investigation 
revealed a positive correlation between the severe degree 
of atherosclerosis and the concentrations of plasma 
cholesterol as well as LDL. Numerous population 
studies have linked raised concentration of total 
cholesterol or LDL–cholesterol in plasma with increased 
incidence of atherosclerotic events. 
HFD which contained high cholesterol, a significant 
increase of different plasma lipids such as TC, TG and 
LDL with a parallel decrease in HDL was observed 
compared with that of control group. 
Consumption of HFD promotes obesity and fat 
accumulation in humans and several animal species, 
including rats, mice, and pigs. 
In this present work, it was planned to Evaluation have 
been selected to study their anti obesity activity in 
experimental animals, rats. Literature survey revealed 
that the Alogliptin from other medicinal uses was used as 
an ethnic folklore medicine for obesity. 
The Alogliptin had significantly reduced the physical 
parameters like body weight, food intake, organ and fat 
pads weight in HFD induced obesity models in rats. 
Alogliptin had significantly reduced the serum 
biochemical parameters like GLU, CHO, TRG, LDL-
CHO, VLDL-CHO levels and increased the HDL levels 
in HFD induced obesity models in rats. 
Thus our present study suggests that Alogliptin possess 
potent obesity activity and increase life span.  
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CONCLUSIONS 
The anti obesity activity of Alogliptin were evaluated in 
HFD induced obesity activities with different models 
respectively. 
Standard reference Sibitramine produced a significant 
anti obesity activity in the selected models from this 
studies it can be concluded that Alogliptin with medium 
and high doses exhibited a significant anti obesity 
activity by reducing body weight, organ and fat pads 
weight and serum GLU, CHO, TRG, LDL and VLDL 
cholesterol levels with an increase in HDL levels in 
HFD induced obesity models in rats. 
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